The University of Texas MD Anderson Cancer Center (US)
Access 250+ million papers and cite this researcher's work with AI assistance
H-index
231
Publications
5467
Citations
264883
i10-index
2488
Want to find and read papers by this researcher? AnswerThis gives you instant access.
Sign Up Free| Title | Year | Citations |
|---|---|---|
Efficacy and Safety of a Specific Inhibitor of the... | 2001 | 5225 |
The 5th edition of the World Health Organization C... | 2022 | 3729 |
Imatinib Compared with Interferon and Low-Dose Cyt... | 2003 | 3555 |
Five-Year Follow-up of Patients Receiving Imatinib... | 2006 | 3469 |
Revised International Prognostic Scoring System fo... | 2012 | 3109 |
Activity of a Specific Inhibitor of the BCR-ABL Ty... | 2001 | 2717 |
A Double-Blind, Placebo-Controlled Trial of Ruxoli... | 2012 | 2028 |
Venetoclax combined with decitabine or azacitidine... | 2018 | 1833 |
Dasatinib in Imatinib-Resistant Philadelphia Chrom... | 2006 | 1768 |
A Tyrosine Kinase Created by Fusion of the <i>PDGF... | 2003 | 1693 |
Hagop M. Kantarjian is a researcher with 5467 publications and 264883 citations. They are affiliated with The University of Texas MD Anderson Cancer Center. Their research focuses on . With an h-index of 231, they are among the top researchers in their field.
Distribution of citations across publications
AnswerThis uses AI to help you search, understand, and cite research from Hagop M. Kantarjian and 250M+ other papers.
Citations per publication by year